PDL BioPharma, Inc. Current Tax Liabilities (Deferred)

Current Tax Liabilities (Deferred) of PDLI for past 10 years: annual, quarterly and twelve month trailing (TTM) including Current Tax Liabilities (Deferred) growth rates and interactive chart.

Highlights and Quick Summary

  • Current Tax Liabilities (Deferred) for the quarter ending September 29, 2015 was $11.6 Million (a 9.13% increase compared to previous quarter)
  • Year-over-year quarterly Current Tax Liabilities (Deferred) increased by 3797.65%
Visit stockrow.com/PDLI for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Current Tax Liabilities (Deferred) of PDL BioPharma, Inc.

Most recent Current Tax Liabilities (Deferred)of PDLI including historical data for past 10 years.

Interactive Chart of Current Tax Liabilities (Deferred) of PDL BioPharma, Inc.

PDL BioPharma, Inc. Current Tax Liabilities (Deferred) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2015 $11.62 $10.64 $6.67
2010 $0.3 $3.59

Business Profile of PDL BioPharma, Inc.

Sector: Other
Industry: Other
PDL BioPharma, Inc. manages various patents in the United States and internationally. The company's patents cover humanization of antibodies. It also offers notes and other long-term receivables services, as well as engages in the equity investment activities. The company was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in 2006. PDL BioPharma, Inc. was founded in 1986 and is headquartered in Incline Village, Nevada.